Program
ADX-038
A development code. Also written as “ADX-038 Dose Level 2” and “ADX-038 Dose Level 1”.
Its studies are mostly in Glomerulonephritis, IGA · Geographic Atrophy · Hemoglobinuria, Paroxysmal, led by ADARx Pharmaceuticals.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| ADARx Pharmaceuticals | 44 open or running | phase 2since May 17, 2023 | May 17, 2023 | Mar 31, 2028phase 2 · NCT05876312 |
Also a collaborator on its studies: novotech-australia-pty-limited.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 17, 2023First study: phase 2 study in Hemoglobinuria, ParoxysmalFirst studyNCT05876312 · 50 planned · Australia, United Kingdom
- May 22, 20252 phase 2 studiesNCT06990269, NCT06989359
- Feb 27, 2026Phase 2 study in Glomerulonephritis, IGANCT07522099 · 30 planned · China
Ahead
- Mar 31, 2028Primary completion: phase 2 study in Hemoglobinuria, ParoxysmalNCT05876312
- Jul 10, 2028Primary completion: phase 2 study in Glomerulonephritis, IGANCT07522099
- Dec 31, 2028Primary completion: phase 2 study in Glomerulonephritis, IGANCT06989359
- Feb 28, 2030Primary completion: phase 2 study in Geographic Atrophy Secondary to Age-related Macular DegenerationNCT06990269
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07522099Glomerulonephritis, IGA · China | 2 | Recruiting | Jul 10, 2028 | 30 |
| NCT06990269Geographic Atrophy Secondary to Age-related Macular Degeneration · United States, Australia, Austria and more | 2 | Recruiting | Feb 28, 2030 | 240 |
| NCT06989359Glomerulonephritis, IGA · United States, Australia, Hong Kong and more | 2 | Recruiting | Dec 31, 2028 | 45 |
| NCT05876312Hemoglobinuria, Paroxysmal · Australia, United Kingdom | 2 | Recruiting | Mar 31, 2028 | 50 |
How it is read
Names in the registry
- “ADX-038”, 3 entries
- “ADX-038 Dose Level 2”, 1 entry
- “ADX-038 Dose Level 1”, 1 entry
Codes read as this program: ADX038.
Conditions, from the studies’ own filings
- Glomerulonephritis, IGA, 2 studies
- Geographic Atrophy, 1 study
- Hemoglobinuria, Paroxysmal, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.